Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled phase 3 trials

BACKGROUND: About one‐tenth of patients with difficult‐to‐treat chronic rhinosinusitis with nasal polyps (CRSwNP) have comorbid non‐steroidal anti‐inflammatory drug‐exacerbated respiratory disease (NSAID‐ERD). Dupilumab, a fully human monoclonal antibody that blocks the shared interleukin (IL)‐4/IL‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Mullol, Joaquim, Laidlaw, Tanya M., Bachert, Claus, Mannent, Leda P., Canonica, G. Walter, Han, Joseph K., Maspero, Jorge F., Picado, Cesar, Daizadeh, Nadia, Ortiz, Benjamin, Li, Yongtao, Ruddy, Marcella, Laws, Elizabeth, Amin, Nikhil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292324/
https://www.ncbi.nlm.nih.gov/pubmed/34459002
http://dx.doi.org/10.1111/all.15067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292324/
https://www.ncbi.nlm.nih.gov/pubmed/34459002
http://dx.doi.org/10.1111/all.15067

Ejemplares similares